Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarity AD: Lecanemab in Early Alzheimer's Disease
jRCT2080224685Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of lecanemab in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (5 arms), sponsored by Eisai Co., Ltd. Started May 2019; status: completed.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on jRCT2080224685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224685.